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Human herpesvirus-8 (HHV-8) is commonly detected in all epidemiologic forms of Kaposi’s sarcoma. Despite the
broad cellular tropism of HHV-8, studies on mucosal shedding of HHV-8 have shown that infectious particles are
restricted to saliva isolated from the oropharynx. We used biotinylated puriﬁed HHV-8 particles in a direct binding
assay to whole clariﬁed human salivary samples isolated from HHV-8-infected and uninfected individuals. We
found that the major binding activity was carried out by a protein of 78-kDa size, which was further characterized as
human lactoferrin (hLf) using 2-D electrophoresis and MALDI-ToF analysis. Preliminary comparison of HHV-8
binding activity of 76 salivary samples from HHV-8-infected and uninfected individuals showed that 7.8% of the
uninfected population exhibited a form of Lf not recognized by HHV-8. Deglycosylation of hLf by PNGase F did not
reduce HHV-8 binding activity, whereas endoproteinase cleavage of native hLf generated a non-glycosylated 8-kDa
peptide recognized by HHV-8 particles and was located at the position Ala606–Tyr679 in the native hLf amino acid
sequence, corresponding to the C-terminal region of the glycoprotein. This work identify the lactoferrin in saliva as
a ligand for HHV-8 and suggests that this glycoprotein could be used as a carrier for the viral particles.
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Herpesviruses are widely disseminated, and approximate-
ly 100 herpesviruses have been partially characterized
and several virus species have been isolated in humans
(Rixon, 1993). Human herpesvirus-8 (HHV-8), also known
as Kaposi’s sarcoma (KS)-associated herpesvirus, was the
last HHV discovered (Chang, 1994). HHV-8 DNA sequences
have been detected in all epidemiologic forms of KS and
HHV-8 is also associated with B cell proliferative diseases,
such as primary effusion lymphoma (PEL) (Cesarman, 1995)
and multicentric Castleman’s disease (MCD) (Soulier, 1995;
Dupin, 2000; Du, 2001). Morphologic studies based on both
immunochemistry and in situ hybridization have demon-
strated that most KS spindle cells are latently infected,
whereas in MCD, the virus is localized in monotypic plas-
mablasts of the mantle zone and 10%–20% of the cells are
lytically infected (de Lellis, 1995; Orenstein, 1997; Dupin,
1999; Sturzl, 1999; Wang, 2004). These tight epidemiologic
relationships suggest a pathogenic role of HHV-8 in these
malignant diseases. In vitro, inoculating cells with HHV-8
typically results in abortive or latent infection (Renne, 1998),
despite the fact that the cell types that can be infected by
HHV-8 are numerous, including human primary B cells,
macrophages (Renne, 1998; Blackbourn, 2000), epithelial,
and endothelial cells (Flore, 1998; Moses, 1999; Cuifo,
2001).
Herpesviruses are characterized by a double-stranded
DNA genome surrounded by a protein capsid, a thick
tegument layer, and a lipid bilayer envelope (Rixon, 1993;
Lo, 2003). To date, the near-complete nucleotide sequence
has been determined from both PEL and KS biopsy spec-
imens (GenBank accession no. KSU75698) (Russo, 1996).
HHV-8 is a rhadinovirus belonging to the Herpesviridae
family, sub-family of gammaherpesviridae. The HHV-8 gen-
ome, which is  140 kb in length, encodes for 90 complete
ORF. ORF 1–75 are designated based on their similarity to
those of Herpesvirus saimiri. In addition, HHV-8 possesses
15 unique ORF designated K1–K15, including K4.1, K4.2,
K8.1, and K10.1 (Russo, 1996; Neipel, 1997). These HHV-8
ORF encode for several glycoproteins that are constituents
of the viral envelope and have been implicated in the inter-
actions that occur between HHV-8 and target cells (Russo,
1996). Initial HHV-8 adhesion is characterized by interac-
tions involving a cellular receptor that is sensitive to heparin,
whereas the penetration of virus into the cell appears to be
linked to a different receptor, not inhibited by heparin (Akula,
2001a, b). To date, it has been shown that two viral surface
glycoproteins are involved in this recognition process. The
HHV-8 surface glycoprotein gB is able to recognize heparin
molecules linked to agarose beads (Akula, 2001a) and the
a3 b1 integrin at the surface of human foreskin fibroblasts
(Akula, 2002). Similarly, the glycoprotein K8.1 is able to
recognize heparin–sulfate (HS) groups at the surface of
endothelial cells (Birkmann, 2001; Wang, 2001).
Seroprevalence reports for HHV-8 antibodies have
shown a distribution linked to the geographic location of
Abbreviations: BSA, bovine serum albumin; HHV-8, human her-
pesvirus-8; hLf, human lactoferrin; PBS, phosphate-buffered
saline; VOA, virus overlay assay
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the population tested. It is very unusual for herpesviruses to
have such heterogeneity in diffusion. Specifically, the prev-
alence is low in North Europe (1%–5%) and moderate in
Mediterranean areas (30%) (Moore, 2000). In a high-risk HIV
positive population (e.g., gay males), the seroprevalence for
HHV-8 increases to 30%–40%, suggesting a sexually trans-
mitted pathogen (Kedes, 1996; O’Brien, 1999). But in chil-
dren from sub-Saharan Africa, where HHV-8 infection is
endemic, the rate of infection can be as high as 50%, cor-
responding to non-sexual transmission routes (e.g., close
contact between individuals) where saliva is a likely source
of virus for new infections (Lennette, 1996; Whitby, 1998;
Engels, 1999; Plancoulaine, 2000; Hudnall, 2003; Mbulait-
eye, 2003). Indeed, it has been shown that viable HHV-8
particles are shed into saliva (Vieira, 1997; Pauk, 2000).
Saliva contains high amounts of mucins and other glyco-
proteins known to play an anti-microbial role by aggregating
microorganisms in the fluid phase, resulting in clearance of
microorganisms from the mouth by swallowing (Slomiany,
1996).
The aim of this study was to characterize proteins and/or
glycoproteins present in saliva that are able to recognize
HHV-8 particles. Using a direct binding assay and samples
of whole saliva from HHV-8-infected individuals, we dem-
onstrate that a glycoprotein, lactoferrin, is specifically rec-
ognized by HHV-8. Screening of a large number of saliva
samples from both HHV-8-infected and uninfected patients
revealed a variation in the HHV-8 binding pattern to lac-
toferrin, with 7.8% of HHV-8 uninfected individuals pos-
sessing an Lf not recognized by the virus. Endoglycosidase
and endoproteinase digestion studies showed that the in-
teraction between HHV-8 and lactoferrin involved the non-
glycosylated C-terminal region of the glycoprotein.
Results
Identiﬁcation of a protein recognized by HHV-8 in hu-
man saliva To evaluate HHV-8 binding activity to saliva
proteins, we developed a solid-phase virus binding assay
by using whole purified virus particles. We show that HHV-8
was able to bind to immobilized saliva in a saturation-de-
pendent manner whereas bovine serum albumin (BSA) used
as negative control was not (Fig 1A). In order to identify the
protein(s) recognized by the HHV-8 particles, we electroph-
oretically analyzed the saliva samples and detected several
protein bands ranging from 29 to 78 kDa (Fig 1B, lanes 2–9).
Using the virus overlay assay (VOA), we found that biotiny-
lated HHV-8 bound to a 78-kDa protein band in all samples
from HHV-8-infected patients (Fig 1C, lanes 2–9) but was
unable to detect BSA (Fig 1C, lane 10). Another protein mi-
grating below the 29-kDa marker was weakly recognized by
HHV-8 in six saliva samples (Fig 1C, lanes 3–8). In order to
validate the test using biotinylated viral particles, we used
concentrated unlabeled HHV-8 particles and detected them
with a specific monoclonal antibody directed against the
K8.1 envelope glycoprotein. We showed that the 78-kDa
band was strongly recognized (Fig 1D, lane 11). Another
protein of about 58 kDa was also recognized, but did not
appear constantly in the samples tested and was not con-
sidered as specific. Since the 78-kDa protein was strongly
recognized by HHV-8 viral particles in all the saliva samples
tested, we chose to focus our work on the characterization
of this protein.
Characterization of the 78-kDa protein of interest Figure
2 shows the separation of the salivary protein mixture by 2-
D gel electrophoresis. The first dimension was an IEF cov-
ering a broad pI range from 10 to 3, which allowed for better
separation. The second dimension was run on 10% SDS-
PAGE, after which the proteins were detected by silver
staining (Fig 2A). Approximately 20 protein spots were ob-
served after separation (Fig 2A). To localize the spots cor-
responding to the 78-kDa protein, a second gel was run in
parallel and subjected to the VOA (Fig 2B). The 78-kDa
protein appeared under two major spots recognized by
biotinylated HHV-8 (Fig 2B, lane 3) and were matched with
the spots in the silver-stained gel (Fig 2A, lane 3). The lower
spot detected in this experiment, migrating at the position
58.1 kDa, was not studied further because the intensity of
recognition by biotinylated HHV-8 was weak and was con-
sidered as non-specific recognition regarding the important
amount of protein detected by silver staining. The protein
spot of interest was excised and characterized by MALDI-
ToF of peptide mixtures after in-gel digestion. Figure 2C
shows a MALDI mass spectrum of a tryptic peptide mixture
produced from the protein spot indicated by an arrow in
Figure1
Binding of whole human herpesvirus-8 (HHV-8) to human saliva. (A)
Clarified saliva from Kaposi’s sarcoma-associated herpesvirus-infected
patients (dark squares) and bovine serum albumin (BSA) used as neg-
ative control (open circles) were immobilized overnight at 371C onto a
96-well plate (25 mg of protein per well) and probed with various con-
centrations of biotinylated HHV-8 ranging from 0.01 to 16 mg per mL for
2 h at RT. Bound biotinylated HHV-8 particles were detected with per-
oxidase–streptavidin as described in Materials and Methods. The re-
sults correspond to the mean of three different samples tested in
triplicate. (B) Salivary proteins from HHV-8-infected patients (lanes 2–9
and lane 11; 50 mg of total protein per lane) and BSA (lane 10; 2 mg)
were separated on 10% SDS-PAGE gels and detected by Coomassie
blue staining. HHV-8 binding activity was detected with (C) biotinylated
HHV-8 (0.1 mg per mL) and (D) concentrated HHV-8 particles detected
by the mouse monoclonal antibodies against K8.1A/B envelope glyco-
protein (10 mg per mL) as described in Materials and Methods. Lane 1
contains molecular mass markers. Arrows indicate the position of the
78-kDa band.
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Fig 2A. Protein sequence database searching identified the
protein as a product of the gene of the human lactoferrin
(hLf) (Table I). Eleven experimentally obtained tryptic pep-
tide masses were found to match predicted peptide masses
to within 0.1 Da, covering 26% of the amino acid sequence.
To control the accuracy of this result, we used commercial
hLf and tested its ability to be recognized by whole HHV-8.
Purified hLf from milk was recognized by biotinylated HHV-
8, which appears onto a doublet relative to the presence of
several glycanic forms of hLf (Fig 3C, lane 2), whereas the
BSA used as a control for specificity was not (Fig 3C, lane
3). Negative controls using peroxidase–streptavidin alone
showed very faint recognition with hLf (Fig 3B, lane 2), again
demonstrating the specific interaction between hLf and
HHV-8. To assess the presence of Lf in the human salivary
samples, we used polyclonal antibodies directed against
hLf (Fig 3D) and showed that in all the samples tested, a
band of 78 kDa migrates at the same position as the com-
mercial hLf used as positive control (Fig 3D, lane 12), and
was specifically detected by the antibodies (Fig 3D, lanes
4–11). Together, these results demonstrate that Lf present in
human saliva samples was recognized by whole HHV-8
particles.
Comparison of HHV-8 binding with Lf in HHV-8-infected
and uninfected populations Plasma samples harvested
from 76 outpatients were first characterized as being in-
fected by HHV-8 by using an assay to screen for the pres-
ence of antibodies against HHV-8. The population was then
separated into two groups: HHV-8 positive (21%) or HHV-8
negative (78.9%) (Table II). Saliva samples were then analy-
zed for the presence of Lf by using biotinylated HHV-8 and
polyclonal antibodies against hLf as probes. In all the sam-
ples studied, the serological detection of antibodies against
HHV-8 and the Lf recognition by biotinylated HHV-8 were
carried out blindly in two separate laboratories. According
to the intensity of HHV-8 binding to Lf, the individuals were
separated into two groups. The first group corresponded to
a positive HHV-8 binding to Lf (Fig 4A, lanes 1–6), whereas
the second group corresponded to no binding to Lf (Fig 4A,
lanes 7 and 8). The recognition of Lf by HHV-8 was 92.1% of
Figure 2
Identification of protein of interest. Clarified human saliva (300 mg of
protein) was separated by 2-D electrophoresis. (A) Proteins were de-
tected by silver staining. (B) Human herpesvirus-8 (HHV-8) binding ac-
tivity was determined with biotinylated HHV-8. Lane 1, molecular mass
markers; lane 2, sample separated only by SDS-PAGE (1-D elect-
rophoresis) (50 mg of protein); lane 3, sample after 2-D electrophoresis.
The arrows indicate the spot excised for identification by MALDI-ToF.
(C) MALDI-ToF spectra obtained for spot of interest. Monoisotopic
peptides masses were used to search protein databases to match and
subsequently identify protein spot.
Table I. Measured and calculated molecular masses for tryptic peptidesa
Mass (Da)b
Position SequenceMeasured Calculated Difference
852.42 852.42 0.00 322–329 (K)DSAIGFSR(V)
935.54 935.54 0.00 270–278 (R)VPSHAVVAR(S)
956.56 956.56 0.00 600–607 (K)RKPVTEAR(S)
1020.52 1020.51 0.01 221–230 (R)DGAGDVAFIR(E)
1097.52 1097.50 0.02 545–553 (R)YYGYTGAFR(C)
1129.62 1129.60 0.02 284–292 (K)EDAIWNLLR(Q)
1195.62 1195.61 0.01 306–316 (K)FQLFGSPSGQK(D)
1459.77 1459.73 0.04 365–376 (R)VVWCAVGEQELR(K)
1974.91 1974.91 0.00 567–584 (K)DVTVLQNTDGNNNDAWAK(D)
2071.04 2071.03 0.01 74–93 (R)ADAVTLDGGFIYEAGLAPYK(L)
2088.08 2088.07 0.01 334–352 (R)IDSGLYLGSGYFTAIQNLR(K)
aThese peptides, which identified the 78-kDa protein spot arrowed in Fig 2, cover 187 of 711 residues, corresponding to 26% sequence coverage.
bMono-isotipic masses.
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the entire population, whereas 7.9% of the individuals ap-
pear to be negative for Lf recognition by HHV-8 (Table II and
Fig 4A). It should be noted that the non-recognition of Lf by
HHV-8 was detected only in the HHV-8 uninfected popu-
lation. In order to ascertain the presence of Lf in these
samples, we tested them using polyclonal antibodies di-
rected against hLf. In all samples, we were able to detect
a 78-kDa band by Coomassie blue staining (Fig 4C, lanes
1–8), which is specifically recognized by antibodies against
hLf (Fig 4B, lanes 1–8).
The protein region of hLf is recognized by HHV-8 hLf is
a glycoprotein containing two N-linked glycans (Spik, 1988).
To demonstrate which part of the glycoprotein was involved
in the recognition by HHV-8, we treated purified hLf with
PNGase F to specifically remove the N-glycans from the
protein backbone and tested it for its ability to recognize
HHV-8 (Fig 5B). After deglycosylation, the hLf was still
strongly recognized by HHV-8 (Fig 5B, lane 3). In parallel,
deglycosylation was assessed by visualization of a shift in
size, detected by Coomassie blue staining after elect-
rophoresis (Fig 5A, lane 3) and by using the RCA-I plant
lectin able to recognize b-linked galactosyl residues in ter-
minal position (Fig 5C) (Green, 1987). We show that the
deglycosylated hLf was no longer recognized by the RCA-I
lectin (Fig 5C, lane 3). These results indicate that the protein
backbone of hLf was involved in the recognition process by
HHV-8.
Characterization of the protein region involved in HHV-8
binding To identify the region(s) of hLf that binds to the
HHV-8 whole particles, we fragmented hLf by using the V8
proteinase able to cut the amino acid sequence at glutamic
acid residue sites. The peptide fragments obtained follow-
ing digestion were electrophoretically separated and tested
for their ability to be recognized by HHV-8 in the VOA (Fig 6).
After digestion, about six to eight major peptide fragments
were obtained (Fig 6A, lane 3) and only one peptide frag-
ment, at about 8 kDa, was recognized by HHV-8 (Fig 6C,
lane 3). The diffused bands at 58.1, 39.8, and 14.3 kDa
recognized by HHV-8, were also obtained in the lane where
non-digested hLf was loaded (Fig 6C, lane 2). These bands
appeared only when the tricine gradient gels were used and
were detected in the absence of biotinylated HHV-8 and
thus are a result of the horseradish peroxidase–streptavidin
detection system (data not shown). In addition, to identify
the glycopeptide fragments released after V8 treatment, we
performed ConA binding assays on the treated samples
(Fig 6B, lane 3). ConA plant lectin was used for its capacity
to recognize mannosyl residues present on N-linked glycan
Figure 3
Characterization of the 78-kDa protein as the human lactoferrin
(hLf). Proteins were separated electrophoretically and transferred to
nitrocellulose membrane. (A) Proteins were detected by Coomassie
blue staining. (B) Non-specific binding activity was detected by per-
oxidase–streptavidin alone. (C) Human herpesvirus-8 (HHV-8) binding
activity was determined by using biotinylated HHV-8 (0.1 g per mL). (D)
Specific hLf detection was realized by using polyclonal antibodies
against hLf. Lane 1 contains molecular mass markers. Lanes 2 and 12
contain purified hLf from human milk (1 mg per lane). Lane 3 contains
bovine serum albumin (1 mg per lane). Lanes 4–11 contain saliva sam-
ples from HHV-8-infected patients (same samples presented in Fig 1,
lanes 2–9). Arrows indicate the position of purified hLf.
Table II. Relationship between the serological human herpes-
virus-8 (HHV-8) patients status and the recognition of lac-






of Lf on blotc
16 M (12), F (4) þ þ (16)
 (0)
60 M (42), F (18)  þ (54)
 (6)
aSaliva samples from 76 outpatients.
bAntibodies to a latent nuclear antigen of HHV-8 were detected by
using an immunofluorescence assay (IFA) on a PEL cell line (BC-3). A
double-blind readout was performed and samples showing specific re-
activity at a 1:100 sera dilution were considered positive for HHV-8 an-
tibodies.
cThe ability of lactoferrin to be recognized by HHV-8 was determined
by using the virus-overlay assay on saliva samples. A representative in-
tensity of Lf recognition pattern by biotinylated HHV-8 is presented in
Fig 4.
Figure4
Representative human herpesvirus-8 (HHV-8) binding profil in
human saliva samples. Clarified saliva samples were separated onto
10% SDS-PAGE, transferred to nitrocellulose membrane, and incubated
with (A) biotinylated HHV-8, (B) polyclonal antibodies against human
lactoferrin (hLf). (C) Proteins were detected by Coomassie blue staining.
Lane 1–8, human salivary samples (50 mg of protein). Lane 9, purified hLf
(2 mg) as positive control. Arrows indicate the position of purified hLf.
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(Bhattacharyya, 1987) on non-treated glycoproteins (Fig 6B,
lane 2). We found that several peptides ranging from 10 to
40 kDa, generated after V8 degradation, were glycosylated
(Fig 6B, lane 3). But the 8-kDa peptide recognized by HHV-8
appeared not to be glycosylated. These results are con-
sistent with those presented in Fig 5, showing that the pro-
tein backbone was involved in the HHV-8 binding to hLf. We
then determined the nature of 20 amino acids from the 8-
kDa peptide fragment by N-terminal sequencing (Fig 7A).
This region was located at positions Ala606–Lys625 in the
amino acid sequence of the mature form of hLf (accession
#AY137470.1) (Velliyagounder, 2003). When combining the
experimentally calculated molecular mass (8.02 kDa) of
the peptide after electrophoresis and the cleavage sites of the
V8 protease, which cleave peptide bonds C-terminally at
glutamic acid residues (Sorensen, 1991), we determined
that the 20 N-terminal amino acid sequence belonged to a
larger peptide starting at position Ala606 and ending at po-
sition Glu679 (N. Dupin, P. A. Grange, V. Calvez, FR 0409969,
patent pending) (Fig 7B). These results show that the bind-
ing of HHV-8 to hLf is located in the C-terminal region of the
glycoprotein.
Discussion
The most common mucosal site where infectious HHV-8
particles have been detected is the oropharynx (Koelle,
1997; Vieira, 1997). Recently, we measured a high HHV-8
load in the oral compartment, which appeared to be inde-
pendent from HHV-8 titers in the blood (Marcelin, 2004).
Although the presence of HHV-8 in saliva is still not well
understood, a model for virus production and mucosal
shedding based on reactivation of the lytic cycle in B cells,
producing extension of infection into capsular epithelial
cells of the tonsil, has been proposed (Corey, 2002). The
route of HHV-8 transmission, however, is still unclear in
Figure 5
Binding of human herpesvirus-8 (HHV-8) to human lactoferrin after
deglycosylation. Purified hLT was subjected to treatment with N-
glycosidase F (PNGAse F). Untreated (lane 2) and treated (lane 3) sam-
ples (2 mg of protein per lane) were separated onto 10% SDS-PAGE
and then transferred onto nitrocellulose membrane. (A) Proteins were
detected by Coomassie blue staining. (B) Detection of HHV-8 binding
activity. (C) Biotinylated RCA-I plant lectin binding activity was used
as deglycosylation control. Lane 1 corresponds to the molecular mass
markers.
Figure 6
Binding of human herpesvirus-8 (HHV-8) to human lactoferrin (hLf)
after proteolytic cleavage. Purified hLf was subjected to V8 end-
oproteinase treatment. Untreated (lane 2) and treated samples (lane 3)
were analyzed in a 10%–20% SDS-tricine gel and transferred to nitro-
cellulose membrane. (A) Protein and peptide fragments were detected
by Coomassie blue staining. Binding activities were detected with (B)
biotinylated ConA plant lectin and with (C) biotinylated HHV-8. Lanes 1a
and 1b correspond to the molecular mass standards Mark 12 (Invitro-
gen) and to the biotinylated molecular mass standards (Sigma Chem-
ical, Paisley, UK), respectively. Arrows indicate the position of the 8-kDa
peptide. Artifactual recognition.
Figure7
Characterization of the 8-kDa human lactoferrin (hLf)-derived pep-
tide. (A) N-terminal sequencing of the 8-kDa peptide recognized by
human herpesvirus-8. (B) Localization map of the 8-kDa peptide in the
mature hLf amino acid sequence (Velliyagounder, 2003). The N-terminal
portion sequenced is presented in italics. Deduced 8-kDa peptide se-
quence position on the hLf amino acid sequence is underlined. Putat-
ives glycosylation sites are presented in bold.
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many cases. If sexual-based transmission is ruled out (e.g.,
in endemic areas), it is clear that the strongest evidence for
a source of transmission of HHV-8 is saliva (Koelle, 1997;
Vieira, 1997; Pauk, 2000; Mbulaiteye, 2004). Moreover, the
high seroprevalency of HHV-8 infection in children from
countries where HHV-8 infection is endemic suggests trans-
mission through close contact (Bourboulia, 1998; Andreoni,
1999).
Saliva is a dilute aqueous solution that contains mucins,
lipids, and proteins, including secretory IgA, lysozyme, am-
ylase, statherin, histatin, and proline-rich proteins. It lubri-
cates and protects the oral cavity and provides a non-
immune defense against pathogens (Wu, 1994; Veerman,
1995). Saliva tested in this study was a mixture of secretions
derived from the parotid, submandibular, and sublingual
glands and was considered as whole saliva. Electrophoresis
of whole saliva revealed several proteins with a major band
at 56 kDa, corresponding to the a-amylase, as has been
previously described (Yao, 2003). High HHV-8 binding ac-
tivity to whole saliva was first indicated by the relatively low
amounts of biotinylated HHV-8 needed for optimum binding
in microtiter wells (i.e. 2 mg per mL, Fig 1A). When testing
the saliva components after electrophoresis, only one band
at 78 kDa, representing less than 5% of the total protein,
was strongly recognized by HHV-8, whereas major protein
bands, as well as serum albumin used as negative control,
were not. These data argue strongly in favor of a specific
recognition. In order to remove any possible contamination
surrounding the 78-kDa band area, saliva components were
separated by 2-D electrophoresis and the spots of interest
were subjected to proteomic analysis and subsequently
characterized as hLf. This result is consistent with previous
studies that have shown the presence of Lf in human saliva
(Tenovuo, 1986).
Lf belongs to the transferrin family of non-heme iron
binding glycoproteins and has a molecular mass of ap-
proximately 80 kDa corresponding to two homologous
globular regions (N-terminal and C-terminal). These two re-
gions are able to bind two Fe3þ ions reversibly and each
contains one N-linked complex biantennate glycans (And-
erson, 1987; Spik, 1988). To date, it is well established that
Lf plays an important role as a primary non-specific defense
mechanism against pathogenic microorganisms, including
viruses (van Der Strate, 2001; Hammer Andersen, 2003). Lf
present in saliva prevents viruses from docking to the
surface of target cells, as previously described for cyto-
megalovirus (Harmsen, 1995), herpes simplex virus (HSV)
(Marchetti, 2004), and hepatitis C virus (Ikeda, 2000). If lac-
toferrin is an effective anti-HHV-8 agent, however, then sa-
liva-borne virions would be neither infectious in vitro, nor the
source of transmission in vivo (Vieira, 1997; Pauk, 2000).
Lactoferrin is a multifunctional glycoprotein that is also able
to recognize sulfated glycosaminoglycans (GAG) like he-
parin-containing molecules (Zou, 1992). In particular, the N-
terminal portion of mature Lf is involved in GAG binding
activity (Mann, 1994). HS groups present on the proteogly-
cans are molecules widely expressed on the surfaces of
cells and are also known to be implicated in the attachment
of HHV-8 particles in cultured cell lines (Akula, 2001a, b;
Birkmann, 2001). The possible role of Lf in the HHV-8 in-
fectious process has not been addressed until now. We
propose that the interactions between HHV-8 and Lf could
lead to the formation of a viral–lactoferrin–GAG–epithelial
cell receptor complex, which may increase the initial infec-
tive viral dose in the vicinity of potential target cells and
increase the risk of infection.
We have shown, however, that some individuals possess
an Lf not recognized by HHV-8. The possible absence of Lf
was dismissed by specific detection of Lf in all of the tested
samples. This differential recognition pattern of Lf by HHV-8
could be explained by (1) a variation in the peptide se-
quence that potentially ablates receptor sites or (2) different
post-translational glycosylation between individuals leading
to modification of recognition sites. The wide distribution of
lactoferrin binding to viruses, including HSV type 1 and 2,
and cytomegalovirus (Fujihara, 1995; Harmsen, 1995), sug-
gests that cell–virus interactions may be regulated by post-
translational modifications of the glycoprotein, rather than
by specific primary protein sequences. This phenomenon
has been described for other viruses like hepatitis B virus,
which binds to the protein part of lactoferrin where the in-
teraction was enhanced following N-glycans removal (No-
zaki, 2003). Also, primate polyoma viruses bind to the
protein region of Lf, but the degree of sialylation of the
glycanic moiety determined recognition function (Keppler,
1995). Therefore, further investigations will be necessary to
explore putative molecular differences between Lf types
that are recognized or not by HHV-8. Moreover, in vitro in-
fection studies in the presence and absence of purified Lf,
as well as purified 8-kDa peptide, will be necessary to
evaluate the impact of Lf on HHV-8 infection.
Preliminary data have shown that Lf not recognized by
HHV-8 was found only in the seronegative individuals, which
may favor a role played by Lf in the HHV-8 infectious proc-
ess. But we cannot exclude the possibility that some HHV-8
seronegative patients are infected by HHV-8 but unable to
mount a detectable serologic response. Therefore, it will be
necessary to screen a larger population in order to evaluate
the significance of HHV-8 binding to Lf versus the se-
ropositivity of the patients assessed by other serological
assays such as ELISA, which has been shown to be more
sensitive, especially in the immunosuppressed population
such as HIV-infected patients.
In this study, we used whole viral particles and therefore
we were unable to more precisely determine the viral en-
velope glycoproteins involved in the recognition process. To
date, two glycoproteins from the HHV-8 envelope, K8.1 and
gB, have been identified for their interactions with cellular
surface receptors of target cells. Particularly, the envelope-
associated glycoprotein gB could mediate cell adhesion via
its RGD motif with the cell surface integrin molecules
(Wang, 2003). We have shown that the non-glycosylated
part of the C-terminal region of Lf is implicated in binding to
HHV-8. Since Lf does not contain HS groups, these data
suggest another possible mode of linkage between HHV-8
and Lf, different from the gB–RGD–integrin interaction. Fur-
ther studies will be conducted to test the ability of purified
recombinant HHV-8 envelope glycoproteins to recognize Lf,
in order to better understand the molecular basis of this
interaction. Following these studies, our long-term goal is to
design small molecule inhibitors that interfere with Lf–HHV-
8 binding, and thus inhibit HHV-8 infection.
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Materials and Methods
Sample collection This study was conducted according to the
Declaration of Helsinki Principles, and the population consisted of
participants visiting the same institution for routine clinical exam-
inations, age ranging from 30 to 87 y, average at 47.5 y. After giving
their written consent to trained staff, blood and saliva were col-
lected from 76 consecutive patients from the same department of
dermatology including patients consulting at the sexually trans-
mitted disease center. Unstimulated fresh whole saliva samples
were collected with a sterile 30 mL plastic tube and diluted 1:2 with
cold sterile phosphate-buffered saline (PBS). Saliva samples were
clarified by centrifugation at 7000  g for 20 min at 41C, and
supernatants were kept at 201C prior to analysis. Blood samples
(20 mL) were collected on EDTA tubes and centrifuged onto a Ficoll
Hypaque layer at 1400  g for 30 min at 201C. Plasma was al-
iquotted in 15 mL tubes and stored at 801C until analysis was
performed. The medical ethical committee of the University of
Paris 5 approved all described studies.
Cell line and virus production BC-3, an HHV-8-positive lymph-
oblastic cell line (ATCC CRL-2277) (Arvanitakis, 1996), was rou-
tinely maintained in RPMI medium supplemented with 2 mM
glutamine, 10% fetal heat-inactivated bovine serum, and antibiot-
ics in a 5% CO2 incubator at 371C (Sigma Chemical, St Louis,
Missouri). Four days post-TPA induction at 2 ng per mL, culture
supernatants were centrifuged at 2000  g for 10 min to remove
cells and cellular debris. The supernatant-containing virus was fil-
tered through a 0.45 mm filter and centrifuged at 46,000  g for 3 h
at 41C. The pellets containing HHV-8 particles were suspended in
cold sterile PBS and centrifuged again as described above. To
obtain concentrated virus preparations, HHV-8 particles were sus-
pended in 2 mL of cold sterile PBS and were quantified using real-
time PCR assay, as described below. Typical values obtained from
1.1 liter of BC-3 cell culture were at 3.4  105 HHV-8 DNA copy per
milliliters of concentrated virus preparation before further purifica-
tion as described below.
Puriﬁcation and HHV-8 labeling A 24%–42% continuous gradi-
ent of Nycodenz in 1 mM potassium phosphate was made as de-
scribed previously (Akula, 2001b). HHV-8 particles were purified by
ultra-centrifugation in a Beckman SW 28 rotor at 70,000  g for 2 h
at 41C as described by Lake and Hutt-Fletcher (Lake, 2000). Frac-
tions (500 mL) were collected from the top and screened for the
presence of the viral particles using quantitative real-time PCR.
Fractions containing viral particles were collected from the 34%–
36% interface, pooled, and dialyzed against PBS to remove Nyco-
denz. Typical values obtained were at 2.8  106 HHV-8 DNA copy
per milliliter of purified preparation. Protein concentration was es-
timated by the method of Lowry using BSA as standard as de-
scribed by Peterson (1983). Biotinylated HHV-8 was prepared
according to the method described by Harlow and Lane (1988) by
reacting purified virus preparation with biotin-NHS at room tem-
perature for 4 h under end-over-end stirring at a ratio of 250 mg of
biotin-NHS per 1 mg of protein. The reaction was stopped by
adding 1 M NH4Cl. Excess of biotin-NHS was removed by dialysis
against PBS at 41C. The biotinylated virus preparations were
stored at 801C before use.
Real-time quantitative PCR To calculate the number of viral DNA
molecules in HHV-8 preparations, a quantitative real-time PCR
assay was performed as described previously (Lallemand, 2000).
Briefly, 50 mL from each fraction was taken and incubated with one
hundred units of DNase at 371C for 1 h to eliminate virion-free DNA.
DNase activity was inactivated by incubating at 651C for 10 min.
DNA was extracted using the QIAamp Blood Kit (Qiagene SA,
Courtaboeuf, France) and subjected to a quantitative real-time
PCR assay combining the quantification of HHV-8 and albumin
gene DNA. This was performed using the fluorescent TaqMan
methodology on an ABI Prism 7700 Sequence Detection System
(PE Applied Biosystems, Forster City, California). Negative controls
for all assays, which included two reactions that contained no
DNA, were run in parallel.
HHV-8 antibody serologic detection Antibodies to a latent nu-
clear antigen (Novocastra Laboratories, Newcastle, UK) of HHV-8
were detected using an immunofluorescence assay (IFA) on a PEL
cell line (BC-3). The IFA was performed using a sera dilution of
1:100 as previously described (Milliancourt, 2001). A double-blind
readout was performed, and samples showing specific reactivity at
a 1:100 were considered positive for HHV-8 antibodies.
Binding assays HHV-8 binding activity was detected using a
VOA. Briefly, saliva was diluted into 50 mM carbonate–bicarbo-
nate, pH 9.6, buffer to yield a protein concentration of 25 mg of
proteins per well, and then immobilized to 96-well polystyrene
plates at 371C overnight. The wells were rinsed three times with 0.2
mL of PBS containing 0.05% Tween-20 (PBS-Tween). Biotinylated
HHV-8 (0.1 mL of 0.1–16 mg per mL in PBS-Tween) was added to
the wells and incubated at room temperature for 1 h. The wells
were rinsed three times with 0.2 mL of PBS-Tween. Peroxidase
conjugated to streptavidin (0.1 mL of 0.5 mg per mL in PBS-Tween)
was added and incubated for 1 h at room temperature. After
washing, bound peroxidase was detected using the chromogenic
peroxidase substrate ABTS.
To identify molecules involved in the HHV-8 binding activity,
salivary proteins (50 mg) were separated by 10% SDS-PAGE and
then transferred to nitrocellulose membranes (0.45 mm pore size),
as described previously (Towbin, 1979). Membranes were then
saturated overnight at 41C in PBS containing 5% BSA, 0.05%
Tween-20 (PBT buffer). Binding activity was detected by incubating
the membranes with 20 mL of PBT containing biotinylated HHV-8
(0.1 mg per mL) for 2 h at room temperature and 2 mL of PBT
containing concentrated HHV-8 particles (from 100 mL of BC-3 cell
culture) for 4 h at 371C followed by three washes with PBT. Bound
biotinylated HHV-8 was detected by incubating the membrane with
peroxidase conjugated to streptavidin (20 mL of 0.5 mg per mL in
PBT) for 1 h at room temperature. After washing, bound peroxidase
activity was detected using 3,30-diaminobenzidine in the presence
of CoCl2 and H2O2 (Harlow and Lane, 1988). Bound HHV-8 par-
ticles were detected by incubating the membrane with mouse
monoclonal antibodies against K8.1A/B envelope glycoprotein
(10 mg per mL; ABI, Columbia, Maryland) for 18 h at room temper-
ature. Membranes were washed three times with PBT, and the
bound mouse antibodies were detected with rabbit polyclonal an-
tibodies against mouse IgG coupled to peroxidase by incubating
the membrane for 45 min at room temperature. After washing,
peroxidase activity was detected as described above. Negative
control experiments using peroxidase conjugated to streptavidin,
anti-K8.1, and anti-IgG antibodies alone were run in parallel.
2-D electrophoresis A 13 cm, pH 10–3, immobilized pH gradient
(IPG strip) (Amersham-Bioscience, Uppsala, Sweden) was rehy-
drated at 201C for 13 h with 250 mL of IEF solution (8 M urea–2%
CHAPS (wt/vol)0.5% IPG buffer, pH 4–7 (vol/vol)0.002%
bromophenol blue) that contained 300 mg of proteins from clari-
fied saliva. Isoelectric focusing was conducted at 201C in four
steps, 1 h at 200 V, 1 h at 500 V, 30 min at 8000 V in a gradient
mode, and 2 h 30 min at 8000 V using the Ettan IPGphor system
(Amersham-Pharmacia). For the second dimension, the IPG strip
was equilibrated for 30 min by rocking in a solution of 6 M urea–
30% glycerol (wt/vol)–0.05 M Tris-HCl–2% SDS (wt/vol)0.002%
bromophenol blue–100 mM DTT and for 30 min in a solution of
6 M urea–30% glycerol (wt/vol)0.05 M Tris-HCl–2% SDS
(wt/vol)0.002% bromophenol blue–400 mM iodoacetamide. The
IPG strip was then applied onto a 10% SDS-PAGE gel. Typically,
two gels were run in parallel for 6 h at 70 mA current constant.
Proteins were detected in one gel by silver staining without the
glutaraldehyde step. The spot of interest was visualized using
the VOA as described previously. The silver-stained gels and the
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membranes were matched and the spots of interest were excised
from the gel.
Characterization of protein of interest by MALDI-ToF Fast
evaporation matrix films were produced as previously described
(Vorm, 1994) by using a saturated solution of 4-hydroxy-a-cyano-
cinnamic acid (Sigma Chemical) in acetone. The protein spots were
subjected to tryptic digestion and the peptide solution was de-
posited on the matrix film and allowed to dry at room temperature.
Sample deposits were rinsed with pure water and subsequently
inserted in the MALDI mass spectrophotometer (Applied Biosys-
tems, Voyager DE super STR) equipped with a 337 nm N2 laser.
Internal mass calibration of all spectra was accomplished by using
the porcine trypsin auto-digestion peptide. Peptide masses were
searched against the SWISS-PROT and Genpept databases.
Western blot Saliva protein samples and purified hLf were sep-
arated onto 10% SDS-PAGE gels and transferred onto nitrocellu-
lose membranes. Membranes were then saturated overnight at
41C in the PBT buffer and incubated at room temperature for 1 h
with the polyclonal IgG rabbit antibodies against hLf (Sigma
Chemical) diluted to 1:1000 in the same buffer. After washing,
bound antibodies were detected by incubating membrane with
goat polyclonal antibodies against rabbit IgG coupled to per-
oxidase (Rockland, Gilbertsville, Pennsylvania) diluted to 1:5000 in
PBT buffer for 30 min at room temperature. Unbound material was
removed by washing and the peroxidase activity was detected as
described above.
Endoglycosidase treatment Purified commercial hLf (500 mg; Si-
gma Chemical) was denatured at 1001C for 5 min in the N-
glycanase digestion buffer (20 mM sodium phosphate–50 mM
EDTA–0.1% SDS–50 mM b-mercaptoethanol) and then digested
with Flavobacterium meningosepticum recombinant in Escherichia
coli PNGase F (N-Glycanase) (80 mU; Prozyme, San Leandro,
California), final volume 532 mL, for 40 h at 371C in the presence of
0.75% NP-40. The enzymatic reaction was stopped by mixing the
sample with the electrophoresis buffer, followed by denaturation at
1001C for 3 min. Deglycosylated hLf was then tested for its ability
to bind biotinylated HHV-8 using the VOA. Deglycosylation was
assessed by a reduction in the apparent Mr as determined in
Coomassie blue-stained SDS-PAGE gels and by reactivity with
RCA-I lectin in an overlay binding assay. Briefly, deglycosylated
and non-deglycosylated hLf were subjected to electrophoresis
and transferred onto nitrocellulose membranes. After blocking the
membranes with 20 mL of (0.5% BSA, 0.15 M NaCl, 0.1 mM CaCl2,
0.01 mM MnCl2 4H2O, 0.01 M HEPES.Naþ (pH 7.5)) (HEPES-
BSA) overnight at 41C, binding activity was detected by incubating
the membranes with 20 mL of HEPES-BSA containing biotinylated
RCA-I plant lectin (0.2 mg per mL; Vector Laboratories, Burlingame,
California) for 1 h at room temperature, followed by washing
(15 min, room temperature) three times with 20 mL of HEPES-BSA.
Bound biotinylated lectin was detected by incubating the mem-
branes with peroxidase–streptavidin (20 mL at 0.5 mg per mL) for
1 h at room temperature. The membranes were washed three times
with 20 mL of appropriate buffer (10 min, room temperature), and
the bound peroxidase activity was detected as described above.
Endoproteinase treatment Purified commercial hLf (500 mg) was
digested with Staphylococcus aureus V8 endoproteinase Glu-C
(50 mg; Roche Diagnostics GmbH, Mannheim, Germany) in diges-
tion buffer (25 mM NH4CO3, pH 7.8), final volume 250 mL, for 18 h
at 271C. The enzymatic reaction was stopped by mixing the sam-
ple with the electrophoresis buffer followed by denaturation at
1001C for 3 min. The peptide fragments were then separated
electrophoretically in a 10%–20% SDS-Tricine gel and transferred
to nitrocellulose membranes. Peptides transferred onto PVDF were
detected by Coomassie blue staining whereas peptides transferred
onto nitrocellulose were tested for their ability to be recognized by
HHV-8 using the VOA. Glycopeptides were detected by using the
ConA plant lectin in the same conditions as described for RCA-I.
N-terminal sequencing For N-terminal determination, 20 mg of
peptide mixture was loaded per lane and gels were electroeluted to
poly(vinylidene difluoride) membranes in the transfer buffer (10%
methanol, 10 mM 3-(cyclohexylamino)-1-propanesulfonic acid (pH
11.0)). Peptides were detected by 0.1% Coomassie blue (wt/vol) in
50% methanol in order to visualize the 8-kDa band prior to exci-
sion. Bands were excised from a single membrane and the material
was subsequently submitted to microsequencing by Edman deg-
radation using a 494HT Procise protein sequencer apparatus from
Applied Biosystems.
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